Replimune Group, Inc. (REPL) is a clinical-stage biotechnology company developing oncolytic immunotherapies, led by RP1 for advanced melanoma. Its analyst coverage has shifted decisively bullish since the RP1 approval. Across seven current, verifiable price targets, the low is $19 (Wedbush and Kempen & Co) and the high is $31 (Leerink Partners), with a simple average of about $23.70, rounded to a $24 central target.
The individual targets underlying that figure are Leerink Partners at $31, Jefferies at $29, Piper Sandler at $27, JPMorgan at $21, BMO Capital at $20, and Wedbush and Kempen & Co at $19 each. The dispersion is unusually wide for a stock this size, reflecting genuine disagreement about how quickly RP1 can convert regulatory success into commercial sales. The overall consensus rating is a "Buy," though the range underscores that the $24 level is a midpoint, not a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
With shares near $19.07, the stock would need to appreciate about 26% to reach the $24 central target — a substantial move. Replimune has already rallied sharply from single-digit levels earlier in 2026 after the RP1 approval, which resolved a period of extreme volatility that had pushed the shares to a multi-year low. The path toward $24 depends less on further regulatory catalysts and more on the company's first quarters of commercial execution, reimbursement dynamics, and whether analyst estimates for product revenue are revised upward.
The clearest support is the shift from a pre-approval to a commercial-stage story. RP1's approval gives Replimune a marketable asset in melanoma, and several analysts raised their targets in late 2026 — Leerink from $19 to $31, Jefferies from $24 to $29, and Piper Sandler from $14 to $27 — signaling rising confidence in the launch trajectory. Additional supportive factors include a strong balance-sheet runway, expansion opportunities for RP1 beyond its initial indication, and momentum in the broader oncology sector.
The main obstacles are commercial and financial. Replimune remains unprofitable, reporting a GAAP (generally accepted accounting principles) net loss of roughly $69.8 million in the quarter ended June 30, 2026, and a successful launch is not assured in a competitive melanoma market dominated by established checkpoint inhibitors. The wide analyst range — with two firms holding targets at $19, essentially the current price — reflects skepticism about how fast RP1 sales will scale. A securities lawsuit and lingering questions around the approval process add legal and reputational overhang, and after a rapid run-up, any launch stumble or guidance disappointment could trigger valuation compression.
Replimune's price action has been exceptionally volatile, with the shares recovering from single-digit territory to trade near their 52-week high. The $24 central target sits almost exactly at the top of that range — approximately the $23.50–$24 zone — making it both a psychological round number and a natural resistance area. A decisive move through that zone would represent a breakout to new highs, while failure there would leave the stock consolidating beneath prior peaks. From what I see, monitoring these levels closely helps clarify the setup.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual analysts may use different assumptions. The most important items to watch are quarterly product-revenue figures from the RP1 launch, any updates on label expansion into additional indications, cash runway and operating-expense trends, and further analyst revisions. Given the stock's sensitivity to regulatory and clinical news, investors should also monitor developments in the securities litigation and any commentary from the FDA or reimbursement bodies.
In my own analysis, I occasionally reference Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum shifts alongside the fundamental picture for names like REPL. These signals draw on technical behavior and broader market data to flag potential changes in trend, which can be useful when weighing execution risks against the current analyst spread.
Reaching $24 would require Replimune shares to rise about 26% from their current level, a substantial but not implausible move given the momentum behind the RP1 approval. The target represents the midpoint of a genuinely divided analyst community: bullish firms see the launch justifying targets of $27 to $31, while more cautious firms remain anchored near $19. The decisive variables are commercial execution, revenue revisions, and whether the stock can hold above its prior resistance zone. The $24 figure is a calculated average of published expectations, not a forecast, and investors should weigh the wide dispersion and execution risk before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 183 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 175 of 218 cases where REPL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The 10-day RSI Indicator for REPL moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 19 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REPL as a result. In 67 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for REPL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 39 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.282) is normal, around the industry mean (3.596). P/E Ratio (-6.863) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of oncolytic immunotherapies
Industry Biotechnology